Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 12 | 2021 | 18 | 4.420 |
Why?
|
| Antiviral Agents | 10 | 2021 | 27 | 2.310 |
Why?
|
| Liver Diseases | 6 | 2022 | 15 | 2.080 |
Why?
|
| Liver Transplantation | 4 | 2021 | 30 | 2.030 |
Why?
|
| Hepatitis C | 7 | 2021 | 15 | 1.950 |
Why?
|
| Pregnancy Complications | 4 | 2022 | 26 | 1.720 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2019 | 15 | 1.070 |
Why?
|
| Coinfection | 2 | 2023 | 6 | 0.920 |
Why?
|
| Humans | 27 | 2023 | 12240 | 0.880 |
Why?
|
| Pregnancy | 7 | 2022 | 193 | 0.870 |
Why?
|
| Sulfonamides | 3 | 2020 | 22 | 0.840 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.790 |
Why?
|
| Quinoxalines | 3 | 2020 | 4 | 0.750 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 6 | 0.740 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2021 | 15 | 0.690 |
Why?
|
| Prejudice | 1 | 2021 | 21 | 0.690 |
Why?
|
| Living Donors | 1 | 2021 | 6 | 0.690 |
Why?
|
| Hepacivirus | 7 | 2021 | 12 | 0.690 |
Why?
|
| HIV Infections | 2 | 2021 | 256 | 0.670 |
Why?
|
| Patient Selection | 1 | 2021 | 111 | 0.660 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 68 | 0.650 |
Why?
|
| Female | 15 | 2022 | 6974 | 0.640 |
Why?
|
| Obesity | 1 | 2021 | 156 | 0.620 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.580 |
Why?
|
| Liver Cirrhosis | 6 | 2022 | 18 | 0.580 |
Why?
|
| Benzimidazoles | 1 | 2018 | 4 | 0.560 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 51 | 0.530 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 2 | 0.470 |
Why?
|
| Gastroenterology | 1 | 2016 | 4 | 0.470 |
Why?
|
| Advisory Committees | 1 | 2013 | 8 | 0.390 |
Why?
|
| Preventive Health Services | 1 | 2013 | 7 | 0.390 |
Why?
|
| Health Policy | 1 | 2013 | 20 | 0.390 |
Why?
|
| United States | 6 | 2021 | 989 | 0.380 |
Why?
|
| Liver Function Tests | 2 | 2022 | 12 | 0.330 |
Why?
|
| Ribavirin | 2 | 2016 | 3 | 0.330 |
Why?
|
| Cyclopropanes | 3 | 2020 | 6 | 0.330 |
Why?
|
| Treatment Outcome | 7 | 2021 | 1478 | 0.320 |
Why?
|
| Middle Aged | 8 | 2021 | 4043 | 0.320 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 47 | 0.290 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 76 | 0.280 |
Why?
|
| Carbamates | 2 | 2020 | 2 | 0.280 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2019 | 3 | 0.260 |
Why?
|
| Hepatitis B | 2 | 2019 | 6 | 0.260 |
Why?
|
| Fatty Liver | 2 | 2019 | 13 | 0.260 |
Why?
|
| Sustained Virologic Response | 3 | 2021 | 3 | 0.260 |
Why?
|
| Adult | 6 | 2021 | 3557 | 0.260 |
Why?
|
| Male | 8 | 2021 | 6815 | 0.230 |
Why?
|
| Young Adult | 4 | 2021 | 863 | 0.220 |
Why?
|
| Aged | 7 | 2020 | 4000 | 0.220 |
Why?
|
| Risk Factors | 3 | 2023 | 1049 | 0.210 |
Why?
|
| Mass Screening | 2 | 2015 | 86 | 0.200 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.200 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 1 | 0.200 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 4 | 0.200 |
Why?
|
| Cost of Illness | 1 | 2023 | 24 | 0.200 |
Why?
|
| Prevalence | 1 | 2023 | 175 | 0.190 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 6 | 0.190 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 4 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 9 | 0.190 |
Why?
|
| Liver | 1 | 2022 | 57 | 0.180 |
Why?
|
| Selection Bias | 1 | 2021 | 4 | 0.180 |
Why?
|
| Fertility | 1 | 2021 | 12 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 10 | 0.170 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.170 |
Why?
|
| Proline | 2 | 2018 | 5 | 0.170 |
Why?
|
| Leucine | 2 | 2018 | 7 | 0.170 |
Why?
|
| Lactams, Macrocyclic | 2 | 2018 | 3 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 46 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 84 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2021 | 42 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 66 | 0.170 |
Why?
|
| Prognosis | 2 | 2021 | 363 | 0.170 |
Why?
|
| Benzofurans | 1 | 2020 | 1 | 0.160 |
Why?
|
| Amides | 1 | 2020 | 9 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 165 | 0.160 |
Why?
|
| Imidazoles | 1 | 2020 | 34 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 36 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2019 | 27 | 0.150 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.150 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2019 | 1 | 0.150 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 546 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2021 | 827 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 2018 | 1 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2018 | 8 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 7 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 312 | 0.140 |
Why?
|
| Graft Survival | 1 | 2018 | 44 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2018 | 30 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 179 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 95 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 158 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2017 | 7 | 0.130 |
Why?
|
| Drug Substitution | 1 | 2017 | 3 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2018 | 295 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2016 | 1 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 1 | 0.120 |
Why?
|
| Macrocyclic Compounds | 1 | 2016 | 1 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 61 | 0.120 |
Why?
|
| Paracentesis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 2 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2020 | 1467 | 0.120 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.120 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 4 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 116 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2016 | 48 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 4 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2015 | 16 | 0.110 |
Why?
|
| Disease Management | 1 | 2016 | 59 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2015 | 29 | 0.110 |
Why?
|
| Hospitalists | 1 | 2014 | 1 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 25 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2014 | 32 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 40 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2009 | 15 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 10 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 90 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 100 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2152 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 400 | 0.070 |
Why?
|
| Adolescent | 2 | 2020 | 989 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2016 | 29 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 15 | 0.050 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 1 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 1 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 14 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 35 | 0.050 |
Why?
|
| Infection Control | 1 | 2021 | 76 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 261 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 6 | 0.040 |
Why?
|
| Comorbidity | 1 | 2018 | 209 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 74 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 324 | 0.030 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 17 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 4 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 15 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 13 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 169 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 72 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 156 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 126 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 695 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 30 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 56 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 186 | 0.020 |
Why?
|